TSLA
Tesla
-- 355.840 NVDA
NVIDIA
-- 138.850 INTC
Intel
-- 23.600 NBIS
NEBIUS
-- 44.490 GCL
GCL Global
-- 3.049 
Ouch! I’m seeing a drop coming?
$ACADIA Pharmaceuticals (ACAD.US)$ Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced top-line results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia. Pimavanserin did not demonstrate a statistically significant improvement over placebo on the study's primary endpoint, the change from baseline to week 26 on the Negative Symptom Assessment-16 (NSA-16) total score (-11.8 vs. -11.1; p=0.4825; effect size=0.07). The safety and tolerability profile of pimavanserin was consistent with previous clinical trials, showing a low rate of adverse events.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call
Jaguar8 : Again.
Trytosaveabit OP Jaguar8 : Yup! Another that’s probably going to plummet?
Jaguar8 Trytosaveabit OP : Big time plummet. I hope nobody is left bagholding
Trytosaveabit OP Jaguar8 : You and me both! Even if it has a great pipeline with others soon to be reported! These are dangerous plays for just that reason! Some are just a huge overreaction! Some are not though.
Jaguar8 Trytosaveabit OP : It’s like NERV
Trytosaveabit OP Jaguar8 : Yup!